<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591626</url>
  </required_header>
  <id_info>
    <org_study_id>17731</org_study_id>
    <secondary_id>H9X-MC-GBGO</secondary_id>
    <nct_id>NCT04591626</nct_id>
  </id_info>
  <brief_title>A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes</brief_title>
  <acronym>AWARD-CHN3</acronym>
  <official_title>A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and efficacy of once weekly&#xD;
      dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese&#xD;
      participants with type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">May 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants achieving HbA1c &lt;7.0%</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of Participants achieving HbA1c &lt;7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Serum Glucose (FSG)</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Change from Baseline in FSG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c &lt;7.0% With no Weight Gain (&lt;0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose &lt;3.0 mmol/L)</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of Participants Achieving HbA1c &lt;7.0% With no Weight Gain (&lt;0.1 kg) and Without Documented Symptomatic Hypoglycemia (Blood Glucose &lt;3.0 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c &lt;7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose &lt;3.0 mmol/L)</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of Participants Achieving HbA1c &lt;7.0% Without Documented Symptomatic Hypoglycemia (Blood Glucose &lt;3.0 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c &lt;7.0% Without Weight Gain (&lt;0.1 kg)</measure>
    <time_frame>Week 28</time_frame>
    <description>Percentage of Participants Achieving HbA1c &lt;7.0% Without Weight Gain (&lt;0.1 kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Glucose From Daily Self-Monitored Plasma Glucose (SMPG) Profile</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Change From Baseline in Blood Glucose From Daily SMPG Profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Mean Insulin Glargine Doses</measure>
    <time_frame>Baseline, Week 28</time_frame>
    <description>Change From Baseline in Daily Mean Insulin Glargine Doses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dulaglutide administered subcutaneously (SC) in combination with insulin glargine given SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC in combination with insulin glargine given SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  have type 2 diabetes&#xD;
&#xD;
          -  are men or nonpregnant women aged ≥18 years at screening&#xD;
&#xD;
          -  have been treated with basal insulin glargine once daily and metformin and/or acarbose&#xD;
             for at least 3 months prior to screening&#xD;
&#xD;
          -  doses of once daily insulin glargine and OAMs must be stable during the 3-month period&#xD;
             prior to screening. Insulin glargine dose is considered stable when all doses during&#xD;
             this period are within the range defined by ±20% of the most commonly used insulin&#xD;
             glargine dose during this same period. Doses of metformin and/or acarbose are&#xD;
             considered stable when doses are unchanged during the same period, and the doses&#xD;
             should be in the inclusive range of the half maximum to maximum approved daily dose&#xD;
             per the locally-approved label&#xD;
&#xD;
          -  have an HbA1c value ≥7.0% and ≤11.0% as assessed by the central laboratory at&#xD;
             screening&#xD;
&#xD;
          -  require further insulin glargine dose increase at baseline per the TTT algorithm based&#xD;
             on the SMBG data (FBG ≥5.6mmol/L) collected during the prior week&#xD;
&#xD;
          -  have stable weight (±5%) ≥3 months prior to screening&#xD;
&#xD;
          -  have body mass index (BMI) between ≥19.0 and ≤35.0 kg/m2 at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have type 1 diabetes (T1D)&#xD;
&#xD;
          -  have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma&#xD;
&#xD;
          -  have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6&#xD;
             months prior to screening&#xD;
&#xD;
          -  have had any of the following CV conditions within the 2 months prior to screening:&#xD;
             acute myocardial infarction (MI), New York Heart Association (NYHA) Class III or Class&#xD;
             IV heart failure, or cerebrovascular accident (stroke)&#xD;
&#xD;
          -  have a known clinically significant gastric emptying abnormality (eg, severe diabetic&#xD;
             gastroparesis or gastric outlet obstruction) or have undergone or plan to have a&#xD;
             gastric bypass (bariatric) surgery or restrictive bariatric surgery (eg, Lap-Band®)&#xD;
             during the course of the study, or chronically take drugs that directly affect&#xD;
             gastrointestinal (GI) motility&#xD;
&#xD;
          -  have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were&#xD;
             diagnosed with any type of acute pancreatitis within the 3 months prior to screening&#xD;
&#xD;
          -  for participants on metformin or metformin and acarbose, have renal disease or renal&#xD;
             dysfunction (eGFR [CKD-EPI] &lt;45 mL/min/1.73 m2), as determined by the central&#xD;
             laboratory; for participants on acarbose, have renal disease or renal dysfunction&#xD;
             (eGFR [CKD-EPI] &lt;25 mL/min/1.73 m2), as determined by the central laboratory&#xD;
&#xD;
          -  have any self or family history of type 2A or type 2B multiple endocrine neoplasia&#xD;
             (MEN 2A or 2B) syndrome in the absence of known C-cell hyperplasia (the only exception&#xD;
             for this exclusion will be for participants whose family members with MEN 2A or 2B&#xD;
             syndrome have a known RET mutation and the potential participant for the study is&#xD;
             negative for the RET mutation)&#xD;
&#xD;
          -  have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or&#xD;
             carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)&#xD;
&#xD;
          -  have serum calcitonin ≥20 pg/mL at screening, as determined by the central laboratory&#xD;
&#xD;
          -  have any hematologic condition that may interfere with HbA1c measurement (eg,&#xD;
             hemolytic anemias, sickle-cell disease)&#xD;
&#xD;
          -  have been treated with any other antihyperglycemia regimen, other than basal insulin&#xD;
             glargine once daily and metformin and/or acarbose, within the 3 months prior to&#xD;
             screening or between screening and baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second People's Hospital of Hefei</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13500507079</phone>
    </contact>
    <investigator>
      <last_name>Wu Dai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18620414146</phone>
    </contact>
    <investigator>
      <last_name>Yan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of the Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13339300885</phone>
    </contact>
    <investigator>
      <last_name>Hongyu Kuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhifeng Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science &amp;Technology</name>
      <address>
        <city>Luoyang Shi</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>15803799788</phone>
    </contact>
    <investigator>
      <last_name>Hongwei Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou Shi</city>
        <state>Henan</state>
        <zip>450014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>15838123695</phone>
    </contact>
    <investigator>
      <last_name>Qingju Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changzhou No.2 People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>051988119776</phone>
    </contact>
    <investigator>
      <last_name>Yun Xue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13805150781</phone>
    </contact>
    <investigator>
      <last_name>Da Long Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18951762690</phone>
    </contact>
    <investigator>
      <last_name>Yi Bing LU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18951670116</phone>
    </contact>
    <investigator>
      <last_name>Jianhua Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Medical University - Nanjing Jiangning Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>211100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13851502586</phone>
    </contact>
    <investigator>
      <last_name>Kun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No. 2 Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou Shi</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13771780309</phone>
    </contact>
    <investigator>
      <last_name>Ji Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13358111966</phone>
    </contact>
    <investigator>
      <last_name>Lan Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peng Duan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <state>Jiangxi</state>
        <zip>337000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yawei Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>86-15843081103</phone>
    </contact>
    <investigator>
      <last_name>Gui Xia Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalian Municipal Central Hospital Affiliated of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xinyu Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13869123309</phone>
    </contact>
    <investigator>
      <last_name>Xiaolin Dong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Putuo District Center Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13611756518</phone>
    </contact>
    <investigator>
      <last_name>Tao Lei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Medical University</name>
      <address>
        <city>XI 'an</city>
        <state>Shanxi</state>
        <zip>710077</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13892879939</phone>
    </contact>
    <investigator>
      <last_name>Ya LI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18980601658</phone>
    </contact>
    <investigator>
      <last_name>Zhenmei An</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18322017516</phone>
    </contact>
    <investigator>
      <last_name>Ming LIU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Jiangyin Hospital of Southeast University Medical College</name>
      <address>
        <city>Wuxi Shi</city>
        <state>Wuxi Shi</state>
        <zip>214400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13901527177</phone>
    </contact>
    <investigator>
      <last_name>Wenlong Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yunnan Province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13888843696</phone>
    </contact>
    <investigator>
      <last_name>Ben Niu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing General Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Yuzhong District</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Song Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tian Feng Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Pinggu District Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>101200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13911080328</phone>
    </contact>
    <investigator>
      <last_name>yufeng li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T2DM</keyword>
  <keyword>LY2189265</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

